First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. - Wikidata - awgldk - TriplyDB

First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.

First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.

http://www.wikidata.org/entity/Q35905061

about

The Valley of Death in anticancer drug development: a reassessment Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine Nanomedicine in the application of uveal melanoma Cancer nanomedicine: from targeted delivery to combination therapy Future prospects of therapeutic clinical trials in acute myeloid leukemia.Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program Summary report of PQRI Workshop on Nanomaterial in Drug Products: current experience and management of potential risks.Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.Recently confirmed apoptosis-inducing lead compounds isolated from marine sponge of potential relevance in cancer treatment.Combination drug delivery approaches in metastatic breast cancer Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.Anthracycline dose intensification in young adults with acute myeloid leukemia.Biomaterials and emerging anticancer therapeutics: engineering the microenvironment.Improving nucleoside analogs via lipid conjugation: Is fatter any better?N-(2-Hydroxypropyl)methacrylamide Copolymer-Drug Conjugates for Combination Chemotherapy of Acute Myeloid Leukemia Development of a preclinical PK/PD model to assess antitumor response of a sequential aflibercept and doxorubicin-dosing strategy in acute myeloid leukemia Recent advances of cocktail chemotherapy by combination drug delivery systems.Pluronic(®) P123/F127 mixed micelles delivering sorafenib and its combination with verteporfin in cancer cells.Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology.Management of refractory acute myeloid leukemia: re-induction therapy or straight to transplantation?Nanoscale delivery systems for multiple drug combinations in cancer.Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs.Novel and emerging drugs for acute myeloid leukemia Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial.MET: a promising anticancer therapeutic target.Late-phase investigational approaches for the treatment of relapsed/refractory acute myeloid leukemia.Combined chemotherapy delivered by nanoparticulate systems: an old concept with modern innovations.Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications.Developmental therapeutics in acute myelogenous leukemia: are there any new effective cytotoxic chemotherapeutic agents out there?Evolving treatment strategies in patients with high-risk acute myeloid leukemia.Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy.Novel therapeutics in acute myeloid leukemia.The drug discovery by nanomedicine and its clinical experience.Materials innovation for co-delivery of diverse therapeutic cargos.Novel drugs for older patients with acute myeloid leukemia.Liposomal forms of anticancer agents beyond anthracyclines: present and future perspectives.Nanomedicine strategies for hematological malignancies: what is next?New treatment for acute myelogenous leukemia.

P2860

Q26861274-31ED82B2-959F-49BB-B462-E9735EA5FB9E Q27000078-FDE06401-B7FD-451D-8CE4-ED938067D559 Q28079572-EC31E18D-715F-4E82-A14C-8646B50C547E Q28083065-2528CAA9-B3EE-4D76-9AC2-BFE5EFB1F7E8 Q30244168-457D2D84-EFB6-4842-B981-58EC12E09927 Q30366990-70BD4BEB-8933-4492-94ED-A5686D645244 Q30456053-A89CEC56-5663-497C-9375-2A6B6A0D5D20 Q34543909-8A26FB72-E9D7-4CA0-A3C8-28A3D2AA5A69 Q34871881-158CEF63-AA2E-490A-9FA5-8A45270B7FE9 Q35546759-EBEF226D-5BD5-425F-BEC5-274655A68645 Q35578368-B9629FDB-0C5C-4255-BA9F-D2090A91A576 Q35955198-82E5B246-ABC6-442B-844B-A4954F7CB98C Q36219674-EE1F8FD6-8D36-407E-A6A9-91065451CA9E Q36612663-27D2ED6A-07E8-4B31-AF69-1A3DBBEF79C4 Q36684345-68B89907-F05C-4EAA-9DC1-2DDC102CBBE5 Q36706248-A0D50BF9-9C22-4948-A789-C93B1B5F2C6F Q36722841-A9B4DC5C-D791-46E2-8845-F554FC0813ED Q36951941-3C8160B9-91D6-4DD0-9651-54921DE638CA Q37206908-90E1C3CA-21F6-4CB9-A4A3-5BD043E6CDBA Q37248795-ACE691F6-F05E-4831-AE64-60034005F09C Q37689857-17B9FE70-7F8A-40C4-880F-D81DBC041971 Q37943251-26C243A2-816A-4569-A2C3-0EF760D08C24 Q37951607-D9E58EEF-BFBF-4381-89BC-BBF300E2E909 Q37983912-140C6BBC-A9C9-4BA8-827E-40F441500829 Q38000711-D56E2668-D84B-4F7C-BA4C-EC4E7967C725 Q38003665-DE102085-C44A-4321-B6FB-B17343F9D51E Q38008247-4FC375C6-A823-4211-8E10-D6B9B33F8DEE Q38042705-FD20DEB7-1DEB-490F-8F8C-48CAF160F3CD Q38074438-704C73B1-C276-4896-9CF3-F516F29FACA8 Q38098301-C669F471-4A04-4C33-A6C3-981DBE162F51 Q38103753-110493DA-B8CC-4F55-A001-ACAC6D9C10C7 Q38179026-52C1C38C-8606-40E2-8622-943CA20C849B Q38183852-AA18F8C8-87DC-49A0-8F75-AEF10CE40D7F Q38196346-6A5CC549-9F51-4FED-AC75-ACD0FC260B39 Q38206349-F2ACBA8B-F342-4B7C-BC4C-A51FB5CFAEEF Q38211033-D586E9DD-5424-45E1-AE87-5C4B801018FD Q38241761-A0DCD4C5-32CE-4FBB-A88F-9EE47AAE2B20 Q38242272-2F585037-F0A6-46D8-A190-BDB396833571 Q38270098-E7A24C08-FF38-47DD-A19C-2DD188D9021B Q38284045-3164F9D6-A954-4EE4-BDE5-698483D83672

P2860

First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.

http://www.wikidata.org/entity/Q35905061

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

First-in-man study of CPX-351: ...... actory acute myeloid leukemia.

@ast

First-in-man study of CPX-351: ...... actory acute myeloid leukemia.

@en

type

label

First-in-man study of CPX-351: ...... actory acute myeloid leukemia.

@ast

First-in-man study of CPX-351: ...... actory acute myeloid leukemia.

@en

prefLabel

First-in-man study of CPX-351: ...... actory acute myeloid leukemia.

@ast

First-in-man study of CPX-351: ...... actory acute myeloid leukemia.

@en

P1433

Q35905061-8002C2BF-7697-4D2B-98A7-B37FCA8C39B4

P1476

Q35905061-F1F8EEAA-6A49-4D0A-9B09-3FCC19810071

P2093

Q35905061-09E19359-0B3C-4130-9789-C01A768C1A9C

Q35905061-13F4D6B3-D589-4680-B219-6C48FF1598D4

Q35905061-18D4B268-09E0-452F-A943-C83803D6C99F

Q35905061-4018B5E4-7884-4892-9151-0B46311FFFCC

Q35905061-41BD838F-4F75-4D59-81F2-81DEF786767C

Q35905061-6DFE59F9-9D54-4BA3-A6C8-3661FCBE4F1C

Q35905061-9996BEC0-1987-4423-A0C1-797FA06F445C

Q35905061-DBD26FDE-CC78-4E90-882D-148D9B0C3BCA

Q35905061-F1E86759-E89F-4946-8544-D649E62E8EAC

P2860

Q35905061-05BCAD75-129F-459A-9A8B-B4A10D54998A

Q35905061-2574DA0B-146C-4273-9859-87B6C67913FA

Q35905061-5CDCA024-8141-4FF9-9F13-EACE0327B9E2

Q35905061-65293001-D20C-4CF7-926A-EE984E9AD757

Q35905061-A058EF6C-9C78-4356-9420-01038C3A31AC

Q35905061-C7FAC680-3B0D-49DF-A8DF-27669458C1A2

Q35905061-E3351D34-81EF-4614-9DDF-BFB237E63EF5

P304

Q35905061-E228F651-9C19-4CB6-9D68-4B08A90FB32F

P31

Q35905061-5AE91B1F-F0CC-49E1-B348-CECB3253B8D6

P356

Q35905061-D2404858-0CE0-46FA-96D4-577F4BB0CC7E

P407

Q35905061-FB24B230-AC11-4FE6-9B3B-AF54CF57A76F

P433

Q35905061-02E8B073-3943-45C8-9BCF-16D17BFCCCC8

P478

Q35905061-6EC2FD4F-E728-4A11-A7F7-8DED07C7B043

P50

Q35905061-4E56D0EB-17C3-420E-8984-BCB720E1B715

Q35905061-C54E9E66-8DCE-49BC-90CA-5EABE7CEEA70

P577

Q35905061-89CCA72E-659B-4348-85ED-28BF45870B7E

P698

Q35905061-6B9C89AC-DC22-41FA-AAD2-27B1C7EAC65F

P932

Q35905061-9E5332AF-7705-4487-856A-98D3C0700E03

P356

JCO.2010.30.5961

P1433

Journal of Clinical Oncology

P1476

First-in-man study of CPX-351: ...... ractory acute myeloid leukemia

@en

P2093

Arthur C Louie

http://www.w3.org/2001/XMLSchema#string

Christine Swenson

http://www.w3.org/2001/XMLSchema#string

Ekatherine Asatiani

http://www.w3.org/2001/XMLSchema#string

Ellen K Ritchie

http://www.w3.org/2001/XMLSchema#string

Eric J Feldman

http://www.w3.org/2001/XMLSchema#string

Gail J Roboz

http://www.w3.org/2001/XMLSchema#string

Jeffrey E Lancet

http://www.w3.org/2001/XMLSchema#string

Jonathan E Kolitz

http://www.w3.org/2001/XMLSchema#string

Lawrence D Mayer

http://www.w3.org/2001/XMLSchema#string

P2860

High-dose daunorubicin in older patients with acute myeloid leukemia.

In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.

Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice.

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts.

Application of theoretical models to chemotherapy protocol design.

Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients.

P304

979-985

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.30.5961

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-01-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21282541

http://www.w3.org/2001/XMLSchema#string

P932

4520927

http://www.w3.org/2001/XMLSchema#string